Pediatric Congestive Heart Failure 

  • Author: Gary M Satou, MD, FASE; Chief Editor: Stuart Berger, MD   more...
 
Updated: Dec 16, 2011
 

Background

The most likely causes of pediatric congestive heart failure depend on the age of the child. Congestive heart failure in the fetus, or hydrops, can be detected by performing fetal echocardiography. In this case, congestive heart failure may represent underlying anemia (eg, Rh sensitization, fetal-maternal transfusion), arrhythmias (usually supraventricular tachycardia), or myocardial dysfunction (myocarditis or cardiomyopathy). Curiously, structural heart disease is rarely a cause of congestive heart failure in the fetus, although it does occur. Atrioventricular valve regurgitation in the fetus is a particularly troubling sign with respect to the prognosis. (See Etiology.)

Neonates and infants younger than age 2 months are the most likely group to present with congestive heart failure related to structural heart disease. The systemic or pulmonary circulation may depend on the patency of the ductus arteriosus, especially in patients presenting in the first few days of life. In these patients, prompt cardiac evaluation is mandatory. Myocardial disease due to primary myopathic abnormalities or inborn errors of metabolism must be investigated. Respiratory illnesses, anemia, and known or suspected infection must be considered and appropriately managed. (See Etiology, Presentation, Workup, and Treatment.)

In older children, congestive heart failure may be caused by left-sided obstructive disease (valvar or subvalvar aortic stenosis or coarctation), myocardial dysfunction (myocarditis or cardiomyopathy), hypertension, renal failure,[1] or, more rarely, arrhythmias or myocardial ischemia. Illicit drugs such as inhaled cocaine and other stimulants are increasingly precipitating causes of congestive heart failure in adolescents; therefore, an increased suspicion of drug use is warranted in unexplained congestive heart failure. (See Etiology and Presentation.)

Although congestive heart failure in adolescents can be related to structural heart disease (including complications after surgical palliation or repair), it is usually associated with chronic arrhythmia or acquired heart disease, such as cardiomyopathy.

Patient education

For patient education information, see the Heart Health Center, as well as Congestive Heart Failure.

Next

Etiology

Congestive heart failure occurs when the heart can no longer meet the metabolic demands of the body at normal physiologic venous pressures. Typically, the heart can respond to increased demands by means of 1 of the following:

  • Increasing the heart rate, which is controlled by neural and humoral input
  • Increasing the contractility of the ventricles, secondary to circulating catecholamines and autonomic input
  • Augmenting the preload, medicated by constriction of the venous capacitance vessels and the renal preservation of intravascular volume

As the demands on the heart outstrip the normal range of physiologic compensatory mechanisms, signs of congestive heart failure occur. These signs include tachycardia; venous congestion; high catecholamine levels; and, ultimately, insufficient cardiac output with poor perfusion and end-organ compromise. (See the image below.)

Chest radiograph shows signs of congestive heart fChest radiograph shows signs of congestive heart failure (CHF)

Systolic dysfunction

Diminished cardiac output is caused by a complex interaction of various factors.[2] Systolic dysfunction is characterized by diminished ventricular contractility that results in an impaired ability to increase the stroke volume to meet systemic demands. Factors such as anatomic stresses (eg, coarctation of the aorta) that contribute to an increased afterload (end-systolic wall stress), as well as neurohormonal factors that increase systemic vascular resistance, also lead to systolic dysfunction.

Diastolic dysfunction

Diastolic dysfunction results from decreased ventricular compliance, necessitating an increase in venous pressure to maintain adequate ventricular filling. Causes of primary diastolic dysfunction include an anatomic obstruction that prevents ventricular filling (eg, pulmonary venous obstruction), a primary reduction in ventricular compliance (eg, cardiomyopathy, transplant rejection), external constraints (eg, pericardial effusion), and poor hemodynamics after the Fontan procedure (eg, elevated pulmonary vascular resistance).

Chronic heart failure

In chronic heart failure, myocardial cells die from energy starvation, from cytotoxic mechanisms leading to necrosis, or from the acceleration of apoptosis or programmed cell death. Necrosis stimulates fibroblast proliferation, which results in the replacement of myocardial cells with collagen. The loss of myocytes leads to cardiac dilation and an increased afterload and wall tension, which results in further systolic dysfunction. In addition, the loss of mitochondrial mass leads to increased energy starvation.

Acute heart failure

During acute congestive heart failure, the sympathetic nervous system and renin-angiotensin system act to maintain blood flow and pressure to the vital organs. Increased neurohormonal activity results in increased myocardial contractility, selective peripheral vasoconstriction, salt and fluid retention, and blood pressure maintenance. As a chronic state of failure ensues, these same mechanisms cause adverse effects.

The myocardial oxygen demand, which exceeds the supply, increases because of an increase in the heart rate, in contractility, and in wall stress. Alterations in calcium homeostasis and changes in contractile proteins occur, resulting in a hypertrophic response of the myocytes. Neurohormonal factors may lead to direct cardiotoxicity and necrosis.

Characteristic findings in children with heart failure

Many classes of disorders can result in increased cardiac demand or impaired cardiac function. Cardiac causes include arrhythmias (tachycardia or bradycardia), structural heart disease, and myocardial dysfunction (systolic or diastolic).

Noncardiac causes of congestive heart failure include processes that increase the preload (volume overload), increase the afterload (hypertension), reduce the oxygen-carrying capacity of the blood (anemia), or increase demand (sepsis). For example, renal failure can result in congestive heart failure due to fluid retention and anemia.

Cardiac rhythm disorders may be caused by the following:

  • Complete heart block
  • Supraventricular tachycardia
  • Ventricular tachycardia
  • Sinus node dysfunction

Volume overload may be caused by the following:

  • Structural heart disease (eg, ventricular septal defect,[3] patent ductus arteriosus, aortic or mitral valve regurgitation, complex cardiac lesions)
  • Anemia
  • Sepsis

Pressure overload may be caused by the following:

  • Structural heart disease (eg, aortic or pulmonary stenosis, aortic coarctation)
  • Hypertension

Systolic ventricular dysfunction or failure may be caused by the following:

  • Myocarditis
  • Dilated cardiomyopathy
  • Malnutrition
  • Ischemia

Diastolic ventricular dysfunction or failure may be caused by the following:

  • Hypertrophic cardiomyopathy
  • Restrictive cardiomyopathy
  • Pericarditis
  • Cardiac tamponade (pericardial effusion)
Previous
 
 
Contributor Information and Disclosures
Author

Gary M Satou, MD, FASE  Director, Pediatric Echocardiography, Co-Director, Fetal Cardiology Program, Mattel Children's Hospital; Associate Clinical Professor, Department of Pediatrics, University of California, Los Angeles, David Geffen School of Medicine

Gary M Satou, MD, FASE is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Society of Echocardiography, and Society of Pediatric Echocardiography

Disclosure: Nothing to disclose.

Coauthor(s)

Nancy J Halnon, MD  Assistant Professor, Division of Pediatric Cardiology (Heart Transplantation and Pediatric Cardiology), Mattel Children's Hospital, University of California, Los Angeles, David Geffen School of Medicine

Nancy J Halnon, MD is a member of the following medical societies: American Academy of Pediatrics, American Heart Association, American Society of Transplantation, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Chief Editor

Stuart Berger, MD  Professor of Pediatrics, Division of Cardiology, Medical College of Wisconsin; Chief of Pediatric Cardiology, Medical Director of Pediatric Heart Transplant Program, Medical Director of The Heart Center, Children's Hospital of Wisconsin

Stuart Berger, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American College of Chest Physicians, American Heart Association, and Society for Cardiac Angiography and Interventions

Disclosure: Nothing to disclose.

Additional Contributors

Lars C Erickson, MD, MPH Associate Professor of Pediatrics, University of Massachusetts Medical School; Consulting Staff, Department of Pediatrics, Division of Pediatric Cardiology, University of Massachusetts Medical Center

Lars C Erickson, MD, MPH is a member of the following medical societies: American Heart Assocation and Sigma Xi

Disclosure: Nothing to disclose.

Ira H Gessner, MD Professor Emeritus, Pediatric Cardiology

Ira H Gessner, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Cardiology, American Heart Association, American Pediatric Society, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Gilbert Z Herzberg, MD Assistant Professor, Department of Pediatrics, Section of Pediatric Cardiology, New York Medical College; Consulting Staff, Department of Pediatrics, Sound Shore Medical Center

Gilbert Z Herzberg, MD is a member of the following medical societies: American Academy of Pediatrics

Disclosure: Nothing to disclose.

Ameeta Martin, MD Clinical Associate Professor, Department of Pediatric Cardiology, University of Nebraska College of Medicine

Ameeta Martin, MD is a member of the following medical societies: American College of Cardiology

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

References
  1. Rajagopal SK, Yarlagadda VV, Thiagarajan RR, Singh TP, Givertz MM, Almond CS. Pediatric heart failure and worsening renal function: Association with outcomes after heart transplantation. J Heart Lung Transplant. Oct 18 2011;[Medline].

  2. Talner N. Heart failure. Heart Disease in Infants, Children, and Adolescents. 1995:1746-73.

  3. Kaza AK, Colan SD, Jaggers J, Lu M, Atz AM, Sleeper LA, et al. Surgical interventions for atrioventricular septal defect subtypes: the pediatric heart network experience. Ann Thorac Surg. Oct 2011;92(4):1468-75. [Medline].

  4. Erickson LC. Medical issues for the cardiac patient. Critical Care of Infants and Children. 1996:259-62.

  5. [Best Evidence] Frobel AK, Hulpke-Wette M, Schmidt KG, Läer S. Beta-blockers for congestive heart failure in children. Cochrane Database Syst Rev. Jan 21 2009;CD007037. [Medline].

  6. Behera SK, Zuccaro JC, Wetzel GT, Alejos JC. Nesiritide improves hemodynamics in children with dilated cardiomyopathy: a pilot study. Pediatr Cardiol. Jan 2009;30(1):26-34. [Medline].

  7. Jefferies JL, Price JF, Denfield SW, Chang AC, Dreyer WJ, McMahon CJ, et al. Safety and efficacy of nesiritide in pediatric heart failure. J Card Fail. Sep 2007;13(7):541-8. [Medline].

  8. Mehra MR. Optimizing outcomes in the patient with acute decompensated heart failure. Am Heart J. Mar 2006;151(3):571-9. [Medline].

  9. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, Segal R, Sharma D, et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J. Jul 2005;150(1):123-31. [Medline].

  10. Rosenthal D, Chrisant MR, Edens E, Mahony L, Canter C, Colan S, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant. Dec 2004;23(12):1313-33. [Medline].

  11. Cvelich RG, Roberts SC, Brown JN. Phosphodiesterase type 5 inhibitors as adjunctive therapy in the management of systolic heart failure. Ann Pharmacother. Dec 2011;45(12):1551-8. [Medline].

  12. Pitt B, Zannad F, Remme WJ, Cody R, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. Sep 2 1999;341(10):709-17. [Medline].

  13. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. Apr 3 2003;348(14):1309-21. [Medline].

  14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. Sep 2 1999;341(10):709-17. [Medline].

  15. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. Dec 1 1996;94(11):2793-9. [Medline].

  16. Blume ED, Canter CE, Spicer R, Gauvreau K, Colan S, Jenkins KJ. Prospective single-arm protocol of carvedilol in children with ventricular dysfunction. Pediatr Cardiol. May-Jun 2006;27(3):336-42. [Medline].

  17. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. Sep 12 2007;298(10):1171-9. [Medline].

  18. [Best Evidence] McAlister FA, Ezekowitz J, Hooton N, Vandermeer B, Spooner C, Dryden DM, et al. Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systematic review. JAMA. Jun 13 2007;297(22):2502-14. [Medline].

  19. Janousek J, Gebauer RA. Cardiac resynchronization therapy in pediatric and congenital heart disease. Pacing Clin Electrophysiol. Feb 2008;31 Suppl 1:S21-3. [Medline].

  20. Beiras-Fernandez A, Deutsch MA, Kainzinger S, Kaczmarek I, Sodian R, Ueberfuhr P, et al. Extracorporeal membrane oxygenation in 108 patients with low cardiac output – a single-center experience. Int J Artif Organs. Apr 2011;34(4):365-73. [Medline].

  21. US Food and Drug Administration (FDA). FDA approves mechanical cardiac assist device for children with heart failure. December 11, 2011. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm283956.htm. Accessed December 16, 2011.

  22. [Guideline] Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. Jun 2010;16(6):e1-194. [Medline].

Previous
Next
 
Chest radiograph shows signs of congestive heart failure (CHF)
Table. Pharmaceutical Agents Used in the Treatment of Congestive Heart Failure
AgentPediatric DoseComment
Preload Reduction
Furosemide1 mg/kg/dose PO or IVMay increase to qid
Hydrochlorothiazide2 mg/kg/d PO divided bidMay increase to qid
Metolazone0.2 mg/kg/dose POUsed with loop diuretic, may increase to bid
Inotropic
DigoxinPreterm infants: 0.005 mg/kg/d PO divided bid or 75% of this dose IV; age 10 y: 0.005 mg/kg/d PO qd or 75% of this dose IV ...
Dopamine5-10 mcg/kg/min IV (usual dosage; maximal dosage may be up to 28 mcg/kg/min)Gradually titrate upward to desired effect
Dobutamine5-10 mcg/kg/min IVGradually titrate upward to desired effect
Epinephrine0.01-0.03 mcg/kg/min IVNot to exceed 0.1-0.3 mcg/kg/min
Milrinone0.3-1 mcg/kg/min IVTypically used without loading dose, especially in unstable patients



Load: 50 mcg/kg IV over 15 min



Afterload Reduction
Captopril0.1-0.5 mg/kg/d PO divided q8h...
Enalapril0.1 mg/kg/d PO divided qd/bid, not to exceed 0.5 mg/kg/dAdults: 2.5-5 mg/day PO qd/bid initially; titrate slowly at 1- to 2-wk intervals; target dose is 10-20 mg PO bid; not to exceed 40 mg/day
LisinoprilNot establishedAdults: Usual dosage is 10mg PO qd (range, 2.5-10 mg)
LosartanInitial dose for hypertension is 0.1 mg/kg/day PO; dosage for treatment of CHF is not established in childrenAdults: 25-100 mg/d PO qd or divided bid
Nitroprusside0.5-10 mcg/kg/min IVMay need to monitor cyanide level
Nitroglycerin0.1-0.5 mcg/kg/min IVVasodilator
Nesiritide0.01-0.03 mcg/kg/min IVInitiate with 0.01 mcg/kg/min



May cause dose-related hypotension



Alprostadil*0.03-0.1 mcg/kg/min IV...
Beta-Blockade[5]
CarvedilolLimited data suggest a therapeutic dosage range of 0.2-0.4 mg/kg/dose PO bid; initiate with lower dose and gradually increase dose q2-3wk to therapeutic range Adults: 12.5-25 mg PO bid



Initiate with 3.125 mg PO bid



MetoprololNot establishedAdults: 25-100 mg PO qd
Selective Aldosterone Antagonists
Spironolactone1-3.3 mg/kg/day PO in single or divided dosesAdults: 12.5-50 mg PO qd; reduce dose to 25 mg qod if hyperkalemia occurs
EplerenoneNot established25-50 mg PO qd
*Prostaglandin E1 (PGE1).
Previous
Next
 
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.